Tech Transfer Roundup: BridgeBio’s R&D Efforts Span New Seven New Agreements

21 Apr 2021

Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.

BridgeBio Pharma, Inc. employs a business model of acquiring rights to or partnering with academic and institutional research in monogenic diseases and genetic cancer indications, often forming single-product portfolio companies to advance its accumulated pipeline. A series of seven new partnerships unveiled on 13 April showcase the Palo Alto, CA-based company’s belief that it is an incredibly fertile time for academic research, an exec told Scrip.

BridgeBio chief business officer Michael Henderson explained in an interview that it is a particularly healthy time for tech transfer...